Remdesivir maker Gilead Sciences sees 10% drop in second-quarter sales as demand for non-coronavirus drugs falls – CNBC

Gilead Sciences sales fell 10% in the second quarter from a year earlier as the coronavirus pandemic weakened need for some of its drugs, including some of its core liver disease treatments.
The compensation … [+2895 chars]